SCHEMBL19583003

SCHEMBL19583003

COc1cc(CNc2ncnc3c2ncn3C2C[C@H](O)[C@@H](CO)O2)cc(OC)c1

nearest known ligand 0.65

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
SLC29A1 Q99808 1/20 0.65
HIF1A Q16665 1/20 0.57
DNMT1 P26358 1/20 0.52
DNMT3B Q9UBC3 1/20 0.52
PAX8 Q06710 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19583147 0.95 SLC29A1 (0.62) SLC29A1HIF1ADNMT1DNMT3BPAX8
SCHEMBL19583019 0.91 SLC29A1 (0.64) SLC29A1
SCHEMBL19583017 0.91 SLC29A1 (0.73) SLC29A1HIF1A
SCHEMBL4540133 0.91 SLC29A1 (0.73) SLC29A1HIF1A
SCHEMBL19583075 0.87 SLC29A1 (0.69) SLC29A1HIF1A
SCHEMBL19582965 0.87 SLC29A1 (0.58) SLC29A1HIF1APAX8
SCHEMBL19582969 0.87 SLC29A1 (0.67) SLC29A1HIF1APAX8
SCHEMBL14713448 0.86 SLC29A1 (0.66) SLC29A1HIF1APAX8
SCHEMBL12579649 0.86 SLC29A1 (0.66) SLC29A1HIF1APAX8
SCHEMBL19582973 0.86 SLC29A1 (0.66) SLC29A1HIF1APAX8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3229771-B1 6-ARYL-9-GLYCOSYLPURINES AND USE THEREOF UNIV PALACKEHO (CZ) 2024-04-03 EP claimed
EP-3229772-B1 6-ARYL-9-GLYCOSYLPURINES AND USE THEREOF UNIV PALACKEHO (CZ) 2020-04-29 EP claimed
US-10550144-B2 6-aryl-9-glycosylpurines and use thereof UNIVERZITA PALACKEHO V OLOMOUCI (CZ) 2020-02-04 US claimed
US-10100077-B2 6-aryl-9-glycosylpurines and use thereof UNIVERZITA PALACKEHO V OLOMOUCI (CZ) 2018-10-16 US claimed
US-20170334943-A1 6-ARYL-9-GLYCOSYLPURINES AND USE THEREOF UNIVERZITA PALACKEHO V OLOMOUCI (CZ) 2017-11-23 US claimed
US-20170326168-A1 6-ARYL-9-GLYCOSYLPURINES AND USE THEREOF UNIVERZITA PALACKEHO V OLOMOUCI (CZ) 2017-11-16 US claimed
EP-3229771-B1 6-ARYL-9-GLYCOSYLPURINES AND USE THEREOF UNIV PALACKEHO (CZ) 2024-04-03 EP disclosed
EP-3229772-B1 6-ARYL-9-GLYCOSYLPURINES AND USE THEREOF UNIV PALACKEHO (CZ) 2020-04-29 EP disclosed
US-10550144-B2 6-aryl-9-glycosylpurines and use thereof UNIVERZITA PALACKEHO V OLOMOUCI (CZ) 2020-02-04 US disclosed
US-10100077-B2 6-aryl-9-glycosylpurines and use thereof UNIVERZITA PALACKEHO V OLOMOUCI (CZ) 2018-10-16 US disclosed
US-20170334943-A1 6-ARYL-9-GLYCOSYLPURINES AND USE THEREOF UNIVERZITA PALACKEHO V OLOMOUCI (CZ) 2017-11-23 US disclosed
US-20170326168-A1 6-ARYL-9-GLYCOSYLPURINES AND USE THEREOF UNIVERZITA PALACKEHO V OLOMOUCI (CZ) 2017-11-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170326168-A1 6-ARYL-9-GLYCOSYLPURINES AND USE THEREOF GART, DAO, GLA SLC29A1 125/4885HIF1A 2000/4885DNMT1 2303/4885
US-10550144-B2 6-aryl-9-glycosylpurines and use thereof GART, DAO, GLA SLC29A1 125/4885HIF1A 2000/4885DNMT1 2303/4885
US-20170334943-A1 6-ARYL-9-GLYCOSYLPURINES AND USE THEREOF UNG, FUT6, GART SLC29A1 59/4885HIF1A 1239/4885DNMT1 1452/4885
US-10100077-B2 6-aryl-9-glycosylpurines and use thereof UNG, FUT6, GART SLC29A1 59/4885HIF1A 1239/4885DNMT1 1452/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.